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http:WHAT THIS PAPER ADDS
This cost-effectiveness analysis directly informed the recommendations made by NICE clinical guideline CG168,
which was commissioned to reduce the uncertainty around the clinical and cost-effectiveness of these treat-
ments. The analysis shows that interventional treatment for varicose veins is a cost-effective use of NHS
resources.Objective: The aim was to investigate the cost-effectiveness of interventional treatment for varicose veins (VV) in
the UK NHS, and to inform the national clinical guideline on VV, published by the National Institute of Health and
Care Excellence.
Design: An economic analysis was constructed to compare the cost-effectiveness of surgery, endothermal
ablation (ETA), ultrasound-guided foam sclerotherapy (UGFS), and compression stockings (CS). The analysis was
based on a Markov decision model, which was developed in consultation with members of the NICE guideline
development group (GDG).
Methods: The model had a 5-year time horizon, and took the perspective of the UK National Health Service.
Clinical inputs were based on a network meta-analysis (NMA), informed by a systematic review of the clinical
literature. Outcomes were expressed as costs and quality-adjusted life years (QALYs).
Results: All interventional treatments were found to be cost-effective compared with CS at a cost-effectiveness
threshold of £20,000 per QALY gained. ETA was found to be the most cost-effective strategy overall, with an
incremental cost-effectiveness ratio of £3,161 per QALY gained compared with UGFS. Surgery and CS were
dominated by ETA.
Conclusions: Interventional treatment for VV is cost-effective in the UK NHS. Speciﬁcally, based on current data,
ETA is the most cost-effective treatment in people for whom it is suitable. The results of this research were used
to inform recommendations within the NICE guideline on VV.
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Visible varicose veins (VV) in the lower limbs are estimated
to affect at least a third of the UK population.1 Although in
some people these veins remain asymptomatic, in othershor now at: Ofﬁce of Health Economics, London, UK.
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//dx.doi.org/10.1016/j.ejvs.2015.07.034they cause symptoms such as pain, aching, or itching and
can have a signiﬁcant negative effect on health-related
quality of life (HRQL). Symptoms may become more se-
vere with time or complications may develop, including
bleeding, thrombophlebitis, skin damage, and ulceration.
One study showed that 28.6% of those who had visible VV
without oedema or other complications progressed to more
severe venous disease after 6.6 years.2 A number of treat-
ments for VV have been shown to increase HRQL3 and are
thought to slow progression of the disease. Such treatments
range from compression stockings (CS), to minimally inva-
sive (endovenous) interventional procedures (principally
ultrasound-guided foam sclerotherapy, UGFS, and
Figure 1. Model diagram. Schematic diagram of the Markov model
designed to compare the cost-effectiveness of treatments for VV.
The arrows denote possible transitions between states. All patients
enter the model through the “First treatment episode” state. The
state “Dead” was included in the model but is not shown in this
diagram.
Treatment of Systematic Varicose Veins 795endothermal ablation, ETA), to surgery. In 2011/2012,
32,704 VV procedures were carried out in the UK NHS,4 yet
national ﬁgures suggest that the number of VV procedures
undertaken in the UK is decreasing each year. In addition,
the UK NHS lags signiﬁcantly behind its European counter-
parts in terms of numbers of procedures per population; a
fourfold difference can be seen between the number of
procedures per million population in the UK compared with
Germany.5 Clearly there is great disparity in the way VV are
treated across Europe.
Recommendations for referral were published by NICE in
2001,6 yet the recommendations have not widely been
adhered to. This has led to a “postcode lottery”, and
precipitated a clinical guideline on the diagnosis and man-
agement of VV, which was commissioned by the NICE.7,8
The aim was to provide guidance on the diagnosis and
management of VV in order to improve patient care and
minimize regional variation across the UK. The guideline was
developed through work with a multi-disciplinary Guideline
Development Group (GDG), and followed the procedures
set out in the guidelines manual.9 The costeutility analysis
(CUA) outlined in this paper was developed as part of the
VV guideline. Cost-effectiveness analysis is integral to the
guideline process, as it allows the interventions that offer
the greatest value for money to be prioritized, where clin-
ically appropriate. Such prioritization is necessary when
faced with budget constraints, as spending in one area of
healthcare displaces spending elsewhere. The relevance of
cost-effectiveness analysis and the implications for the
treatment of VV have been discussed elsewhere.10METHODS
An overview of the methods for this economic evaluation
are presented here; full details can be found in Appendix L
to the full guideline.7
An economic analysis was conducted to compare the
cost-effectiveness of surgery (stripping and ligation), ETA
(radiofrequency ablation, RFA, and endovenous laser abla-
tion, EVLA, considered together), UGFS, and CS, as these
were the treatments considered in the guideline. Note that
the decision to consider RFA and EVLA together was made
by the GDG, as the basic principle of ultrasound-guided
endovenous thermal ablation is shared between the tech-
niques and the results are very similar. For a discussion on
the potential differences in costs between RFA and EVLA
please refer to Appendix L of the full guideline.7 The model
considered adults with primary unilateral great saphenous
vein (GSV) incompetence (chosen for being a common
presentation of VV), who were potentially suitable for
treatment by any of the four treatment options.
A Markov model was developed (Fig. 1). All patients were
assumed to have a ﬁrst treatment episode, which
comprised an initial treatment and top-up treatment where
necessary. Following this, the treatment episode was
considered to be complete. Patients could experience clin-
ical recurrence of VV (deﬁned as development of symptoms
of VV in a treated limb), the probability of which differed bytreatment option. A proportion of recurrent patients were
assumed to undergo a second treatment episode (6 months
after the onset of the recurrence), after which they could
experience recurrence for a second time, but would not
receive further treatment.
CS was modelled separately to the other three treatments,
as the outcomes of completed treatment and clinical recur-
rence are not clinically meaningful when considering this
management technique. Inputs were based on clinical evi-
dence identiﬁed in the systematic review undertaken for the
guideline, supplemented by additional data sources as
required. The model cohort was assumed to be 65% female
and have a starting age of 50, which was the approximate
mean of all the patients from the included trials (all-cause
mortality rates are age and gender speciﬁc but are unrelated
to health state or treatment strategy). The model was built
probabilistically to take account of the uncertainty sur-
rounding each input parameter. Various deterministic sensi-
tivity analyses were also undertaken to test the robustness of
the model to different assumptions and data sources
(deterministic sensitivity analysis involves varying the inputs
of the model, in order to investigate the effect they have on
the results). The model was built with a 1-month cycle length
(chosen as this was deemed to be the minimum clinically
meaningful time interval to detect differences between in-
terventions), over a time horizon of 5 years in the base case. A
time horizon of 5 years was chosen as clinical data were only
available for a follow-up of 3 years, and the GDG did not feel
Table 1. Overview of parameters and parameter distributions used in the model.
Parameter description Point estimate Probability distribution Distribution parameters Source
Utility weights
Primary VV 0.764 Beta a ¼ 37600, b ¼ 12800 PROMs3
Change in utility (from baseline)
post treatment
þ0.091 Lognormal m ¼ 2.397, s ¼ 0.0007 PROMs3
Change in utility (from baseline)
due to recurrent VV
0.093 Lognormal m ¼ 2.206, s ¼ 0.0128 Beresford et al.13
Conservative care
(relative to surgery at 1 year)
0.101 Normal m ¼ 0.101, s ¼ 0.0198 Michaels et al.15
Transition probabilities
Probability of requiring top-up treatment (within 2 months post treatment)
Surgery 5% Deterministic SA only GDG estimate
Endothermal 5% Deterministic SA only GDG estimate
Foam Sclerotherapy 20% Deterministic SA only GDG estimate
Conservative care NA
Probability of recurrence (per month)
Surgery 0.0083
(SD 0.0031)
Point estimate and uncertainty from NMA
Endothermal 0.0058
(SD 0.0134)
Point estimate and uncertainty from NMA
Ultrasound-guided foam
sclerotherapy
0.0091
(SD 0.0037)
Point estimate and uncertainty from NMA
Conservative care NA
Cost (£)
Surgery £908 Gamma See Appendix L to the full
guideline e only NHS reference
cost components modelled
probabilistically
See Appendix L to the
full guideline for full
breakdown of costs
and sources
Endothermal £624 Gamma
Ultrasound-guided foam
sclerotherapy
£315 Gamma
Conservative carea £234 Deterministic SA only
Additional cost associated
with retreatment
£417 Gamma See Appendix L to the full
guideline e only NHS reference
cost components modelled
probabilistically
See Appendix L to the
full guideline for full
breakdown of costs
and sources
GDG ¼ guideline development group; NMA ¼ network meta-analysis; PROMs ¼ patient-reported outcome measures; SA ¼ sensitivity
analysis; SD ¼ standard deviation.
a This is an annual cost (ﬁrst year incurs an additional £15).
796 G. Marsden et al.that basing long-term extrapolation on arbitrary assumptions
in the absence of data was appropriate.Probabilities
Clinical recurrence (network meta-analysis). A network
meta-analysis11 was conducted to calculate treatment-
speciﬁc probabilities of clinical recurrence. In order to ac-
count for the different follow-up times of the various trials, an
underlying Poisson process with a constant event rate was
assumed for each trial arm, and a complementary logelog
(cloglog) link function used to model the event rate. A key
assumption employed here is a constant hazard of recurrence
e this was deemed to be a reasonable simplifying assumption
as the time horizon of the model is relatively short.
Surgery was chosen as the baseline comparator as it
featured in all the trials. The baseline hazard was estimated
on the cloglog scale through a meta-analysis of the surgery
arms of the included trials. The resulting predictive distri-
bution for the baseline hazard was combined with
treatment-speciﬁc hazard ratios resulting from the networkmeta-analysis to calculate the probability of clinical recur-
rence for each treatment. The codes for both the baseline
and relative effects models were adapted from that pro-
vided on the NICE Decision Support Unit (DSU) website,12
and run in WinBUGS 1.4. The baseline and relative effects
models were run for a sample of 50,000 iterations after an
initial ‘burn in’ of 50,000 iterations. Convergence was
checked through examination of trace and history plots.
Top-up treatment and re-treatment. The model assumed
that all top-up treatments were UGFS; this assumption does
not impact recurrence rates, it only impacted costs, which
were thoroughly explored through sensitivity analyses. The
purpose here was to include a cost of top-up treatment to
capture the increased cost if some procedures require more
top-ups than others. The choice of top-up treatment was
therefore not of primary relevance.
Not all patients were expected to be retreated after
experiencing clinical recurrence; the GDG estimated that
75% of patients would receive further interventional
treatment, and it was assumed that the remaining 25%
Figure 2. Network of trials compared in the network meta-analysis.
Treatment of Systematic Varicose Veins 797would receive CS. The proportion of patients undergoing
each modality of re-treatment was assumed to be inde-
pendent of the modality of their initial treatment (Table 1).
Utilities
In CUA, measures of health beneﬁt are valued in terms of
quality adjusted life years (QALYs). A QALY is a measure of a
person’s length of life weighted by a valuation of their HRQL
over that period. The weight used is called a utility value,
which is a measurement of the preference for a particular
health state, with a score usually ranging from 0 (death) to
1 (perfect health). Utility inputs for the model were taken
from the patient-reported outcome measures (PROMs),3
and are documented in Table 1. The baseline value was
used in the model to represent the utility of a patient with
primary VV, that is when a patient ﬁrst receives treatment.
The health gain after treatment was used to model the
increase in utility associated with treatment.
The HRQL associated with recurrent VV was taken from
Beresford et al.,13 and the SF-36 data provided in the paper
were mapped to EQ-5D utility scores, using an established
equation developed by Ara and Brazier.14
As mentioned previously, CS was modelled separately to
the main analysis. The difference in utility between patients
undergoing surgery and CS was used to calculate the dif-
ference in QALYs over time between these two treatments.
The difference in utility between these two treatments was
taken from Michaels et al.15 (Table 2) as this was the only
paper found to report such data. For the probabilistic
analysis the difference between utility following CS and
surgery was modelled using a Normal distribution to allow
positive and negative differences.
Costs and resource use
Costs were expressed in 2013 UK pounds and were
considered from a UK NHS and personal social services
perspective. Costs and QALYs were both discounted at 3.5%
per annum, in accordance with the NICE reference case.
NHS reference costs do not distinguish between the
various treatments for VV, so the GDG decided on a
bottom-up costing approach. Resource use was estimated
by the clinical members of the GDG, and where possible
unit costs for these resources were collected from nation-
ally available lists, such as the NHS reference costs or the
PSSRU. Only NHS reference cost components were
modelled probabilistically, and this was done using a
Gamma distribution. A summary of the costs used in the
model is presented in Table 1; the breakdown of the costs is
presented in Appendix L of the full guideline. Costs were
subject to extensive deterministic sensitivity analyses.Table 2. EQ-5D data for conservative care.
Study Relevant comparators
Michaels et al.15 (Group 3 only: severe VV) Surgery
Conservative careCalculating cost-effectiveness
Incremental cost-effectiveness ratios (ICERs) are commonly
used in cost-effectiveness analysis. ICERs are calculated by
dividing the difference in costs between two alternatives by
the difference in QALYs. Then, if the resulting ICER falls
below a given cost per QALY threshold, the more clinically
effective treatment is considered to be cost effective. The
cost per QALY threshold suggested by NICE is £20,000 per
QALY gained.16
For a given cost-effectiveness threshold, cost-
effectiveness can also be expressed in term of net mone-
tary beneﬁt (NMB). This is calculated by multiplying the
total QALYs for a comparator by the threshold cost per
QALY value (£20,000 in this case) and then subtracting the
total costs (formula below).
NMB ¼ MeanQALYs  £20,000 e MeanCosts
The most cost-effective strategy is that with the highest
NMB. Both methods of determining cost effectiveness will
identify the same optimal strategy.RESULTS
Network meta-analysis
Eight studies were identiﬁed from the clinical effectiveness
review that included clinical recurrence as an outcome.17e
24 The network of included trials is shown in Fig. 2, with
the number of trials included for each pair-wise comparison
noted in parentheses. Full details of the included data are
provided in Appendix L of the full guideline.
The ﬁnal treatment-speciﬁc probability estimates can be
seen in Table 1. The table indicates that ETA was associated
with the lowest probability of clinical recurrence per month.
These estimates were used to parameterize treatment ef-
fects in the decision model.Utility values
Baseline 3 months 6 months 12 months 24 months
0.76 (0.19)
0.77 (0.18)
NR
NR
0.89 (0.13)
0.80 (0.17)
0.87 (0.14)
0.78 (0.18)
0.84 (0.21)
0.85 (0.17)
Figure 3. Cost-effectiveness plane showing incremental cost and
QALYs per patient expected with each strategy (base case, prob-
abilistic analysis).
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CS and surgery dominated in the base case, as they pro-
vided fewer QALYs at increased cost compared with ETA
(Table 3 and Fig. 3). ICERs are not applicable for the
dominated strategies; therefore, only one ICER was calcu-
lated, comparing UGFS with ETA. Net monetary beneﬁt
(NMB) is calculated for all strategies.
ETA produced the greatest QALY gain, and was therefore
the most clinically effective treatment, yet it came at an
additional cost compared to UGFS, of £151 (note that this
includes the downstream costs of top-up treatments and
clinical recurrence, as well as the cost of the initial proce-
dure). Using the mean costs and QALYs generated by the
probabilistic sensitivity analysis, the ICER of the ETA to FS
was £3,161. This is below the NICE threshold of £20,000 per
QALY gained, and therefore ETA was found to be the cost-
effective strategy.
In this analysis, an area of particular uncertainty is the
costs. Yet, sensitivity analyses revealed that the model is
robust to changes in relative costs. If the costs of surgery,
UGFS, and conservative care remain as speciﬁed in the base
case, ETA remains cost-effective even with increases in cost
of up to £681. A wide range of further sensitivity analyses
was undertaken in which key assumptions and parameters
were varied. Baseline recurrence rate, utility values, time
horizon, top-up rates, and modality of retreatment were
among the inputs subject to such variation. An analysis was
also conducted to investigate the impact of conducting ETA
without concurrent phlebectomies. None of the sensitivity
analyses changed the optimum result. This shows that
although uncertainty surrounds model inputs and assump-
tions, variation within reasonable ranges does not change
the results. Probabilistic analysis revealed that ETA had a
probability of being cost-effective of 71% (at the threshold
of £20,000 per QALY gained), followed by UGFS, which had
a probability of being the most cost-effective option of 23%.
The probability of each treatment being cost-effective at
different threshold values is shown in Fig. 4. Full details of
all sensitivity analyses and associated results are provided in
Appendix L of the full guideline.
DISCUSSION
The most important ﬁnding of this study is that all inter-
ventional treatments (surgery, ETA, and UGFS) for VV are
cost-effective compared with compression therapy. The
study also found that ETA is cost-effective compared with
surgery and UGFS.
However, the ﬁndings of this study need to be carefully
interpreted in the context of clinical practice. The model isTable 3. Mean base case results (probabilistic).
Treatment Mean per patient Cost-effecti
QALYs Cost NMB
Conservative care 3.55 £1 102 £69 965
Surgery 3.69 £1 222 £72 554
UGFS 3.67 £718 £72 681
ETA 3.72 £869 £73 484based upon the treatment of unilateral GSV VV, which,
although arguably the most common, are only one of many
different presentations (bilateral, recurrent, small saphe-
nous vein either alone or in combination with GSV). The
model also assumes that the patient can be treated by all
four modalities, which may rarely be the case.
In addition, the quantity and quality of data available for
the NMA were limited, particularly for UGFS, for which only
two trials were included. Of note, some concern was
expressed by members of the GDG that the foam technique
used in these trials was inadequate (1 trial used 3% poli-
docanol, 2 mL of solution mixed with 8 mL of air,22 and the
other used 3% polidocanol in a sclerosant to air ratio of
1:424). Therefore, although the data comparing surgery with
ETA is considered to be reasonably robust, there are re-
sidual concerns over the data for UGFS. Interestingly, results
from one recent study25 suggest little difference in quality
of life outcomes between surgery, ETA, and UGFS over a 1-
year period, despite differences in clinical outcomes. Clearly
additional research is required in this area, a ﬁnding echoed
by a recent HTA-funded systematic review.26 Finally, there
are as yet very limited data available on the long-term
durability of ETA or UGFS, which makes predicting out-
comes beyond a few years problematic. Clearly further
long-term cohort and controlled studies are required.
This study reinforces the ﬁndings of Gohel et al.,27 who
found, based on a UK CUA, that RFA or EVLA performed as
an outpatient procedure, or surgery performed as a day
case procedure, are likely to be cost-effective treatments.
The analysis presented here goes beyond that carried out
by Gohel et al., by combining all available evidence in a
network meta-analysis, and by including additional details
such as the ongoing potential for recurrence of varicosities.veness at a threshold of £20,000 per QALY gained
Rank Probability of being cost effective
4 4%
3 3%
2 23%
1 71%
Figure 4. Cost-effectiveness acceptability curve.
Treatment of Systematic Varicose Veins 799A further recent UK CUA26 found FS to be cost-effective
compared with surgery, EVLA, and RFA. This study differed
from the model presented here, as the analysis focused on
technical (as opposed to clinical) recurrence, which included
outcomes such as reﬂux, recanalization and incomplete
obliteration of the vein all analysed together in an NMA.
Using this method, little clinical difference was found be-
tween the strategies, and the model was therefore largely
driven by the cost of the treatments. FS was the cheapest
treatment; therefore, this was the cost-effective option in
the base case. The GDG discussed this analysis at length,
and raised concerns about the use of technical recurrence
as a key clinical outcome (as, for example, recurrent reﬂux
may not lead to recurrent symptoms), and about the cost
ﬁgures used. Speciﬁcally, the GDG did not agree that EVLA
and RFA would be more costly than surgery.
Several partial, pairwise, UK economic evaluations have
also been published, where costs have been collected
alongside randomized trials.28e30 Bountouroglou et al.29
found that foam sclerotherapy conducted under local
anaesthetic costs £672.97, whereas surgery under general
anaesthetic costs £1,120.64; Subramonia and Lees30 found
endothermal treatment to be more costly than surgery
(£1,275.90 compared with £559.13), although the tech-
nique that was used for endothermal ablation in this trial is
now considered out of date; Lattimer28 found that foam
sclerotherapy was substantially less costly than endo-
thermal treatment (£230.24 vs. £724.72). These studies are
of limited value when attempting to assess which out of all
the available treatments are cost-effective, as they provide
only pairwise comparisons, have relatively short follow up
times, and generally don’t account for recurrence or HRQL.
Throughout this analysis ETA and UGFS were assumed to
take place in an outpatient setting (under local anaesthetic),and surgery as a day case procedure (under general
anaesthetic). The analysis has not considered different set-
tings of treatment, for example ETA as a day case proce-
dure. Nevertheless, sensitivity analysis did show that the
optimal strategy was fairly robust to increases in the cost of
ETA and so if ETA under local anaesthetic was not consid-
ered suitable for a patient, endothermal treatment under
general anaesthetic may represent a cost-effective
alternative.
The results of this CUA were used to inform guideline
development; therefore, ETA is the recommended strategy
for treatment of truncal VV in the UK NHS, providing it is
clinically and anatomically suitable for the patient. By
logical extension the GDG expect that these results will hold
for the treatment of the small saphenous vein,31,32 for
recurrent varicose veins, and also for bilateral treatment,
again providing that ETA is deemed suitable for the patient
in question. It is acknowledged within the guideline that
ETA may not be suitable for all patients. If ETA is not suit-
able, then UGFS is considered to be the cost-effective op-
tion. If UGFS is not suitable either, surgery is the optimal
strategy provided the patient is suitable and willing to be
operated on.
The clinical data employed in the analysis above has been
collected from around the world, yet the cost data is spe-
ciﬁc to the UK. The implication of this is that where other
healthcare systems (either state or privately funded) face
similar costs, and treatments can be expected to have a
similar impact on quality of life, the conclusions may
generalize. Indeed sensitivity analyses have shown that our
conclusions are robust to substantial changes in relative
costs, indicating that interventional treatment for VV may
be cost-effective in various other scenarios or settings. The
cost-effectiveness acceptability curve (Fig. 4) shows how the
800 G. Marsden et al.probability of each intervention being cost-effective at
different values of the cost-effectiveness threshold, which
may be faced in other countries.
CONCLUSION
The model found that all interventional treatments (surgery,
ETA, and UGFS) for VV are cost-effective compared with
compression therapy. Based on currently available data, it is
likely that endothermal treatment is the most cost-effective
strategy for people in whom all treatments are suitable.
When ETA is not deemed suitable for a patient, UGFS is
likely to be the optimal strategy. Surgery represents the
optimal choice if neither ETA nor UGFS is thought suitable.
The guideline recommends offering treatment in accor-
dance with these ﬁndings for people with symptomatic VV.
This guidance will most likely increase the number of re-
ferrals to vascular specialists, as it challenges the traditional
practice of providing conservative care as a “low cost”
alternative to interventional treatment. NICE estimates that
much of the costs arising from the increase in referrals will
be offset by a decrease in the number of expensive surgical
procedures in favour of the cost-effective alternative,33 ETA.
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